RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+4%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$7.22B
AUM Growth
+$7.22B
(+16%)
Cap. Flow
+$1.06B
Cap. Flow
% of AUM
14.76%
Top 10 Holdings %
Top 10 Hldgs %
44.55%
Holding
109
New
17
Increased
10
Reduced
8
Closed
14
Top Buys
| 1 |
CLYM
Climb Bio, Inc. Common Stock
CLYM
|
$236M |
| 2 |
Invivyd
IVVD
|
$226M |
| 3 |
Cytek Biosciences
CTKB
|
$206M |
| 4 |
ICVX
Icosavax, Inc. Common Stock
ICVX
|
$171M |
| 5 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
$171M |
Top Sells
| 1 |
Axsome Therapeutics
AXSM
|
$112M |
| 2 |
Novavax
NVAX
|
$95.8M |
| 3 |
WHWK
Whitehawk Therapeutics, Inc. Common Stock
WHWK
|
$68.9M |
| 4 |
Curis
CRIS
|
$57.6M |
| 5 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$56.4M |
Sector Composition
| 1 | Healthcare | 99.06% |
| 2 | Financials | 0.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma
ASND
$11.8B
| $1.18B | 16.32% | 7,387,900 +581,559 | +9% | +$92.7M |
|
|
2
Novavax
NVAX
$1.21B
| $435M | 6.03% | 2,097,794 -462,124 | -18% | -$95.8M |
|
|
CLYM
3
Climb Bio, Inc. Common Stock
CLYM
$151M
| $236M | 3.28% | +13,150,849 | New | +$236M |
|
|
4
Invivyd
IVVD
$204M
| $226M | 3.13% | +5,340,130 | New | +$226M |
|
|
FMTX
5
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $209M | 2.9% | 9,011,651 | – | – |
|
|
6
Cytek Biosciences
CTKB
$527M
| $206M | 2.85% | +9,607,028 | New | +$206M |
|
7
Atea Pharmaceuticals
AVIR
$267M
| $190M | 2.64% | 5,427,655 +59,204 | +1% | +$2.08M |
|
8
Janux Therapeutics
JANX
$1.37B
| $188M | 2.6% | 8,670,644 | – | – |
|
9
Vor Biopharma
VOR
$250M
| $174M | 2.42% | 11,120,973 | – | – |
|
|
JBIO
10
Jade Biosciences, Inc. Common Stock
JBIO
$258M
| $173M | 2.4% | 8,263,982 | – | – |
|
|
ICVX
11
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $171M | 2.37% | +5,779,347 | New | +$171M |
|
|
DICE
12
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $171M | 2.36% | +5,208,911 | New | +$171M |
|
|
CNTB
13
Connect Biopharma
CNTB
$115M
| $169M | 2.35% | 6,991,003 | – | – |
|
14
Nkarta
NKTX
$151M
| $156M | 2.16% | 5,605,129 | – | – |
|
15
Acumen Pharmaceuticals
ABOS
$82.4M
| $145M | 2.01% | +9,770,773 | New | +$145M |
|
16
TG Therapeutics
TGTX
$4.65B
| $136M | 1.89% | 4,098,332 +755,589 | +23% | +$25.1M |
|
17
Travere Therapeutics
TVTX
$1.56B
| $136M | 1.89% | 5,614,428 | – | – |
|
18
Tyra Biosciences
TYRA
$675M
| $127M | 1.76% | +7,236,454 | New | +$127M |
|
19
MacroGenics
MGNX
$112M
| $124M | 1.72% | 5,943,594 | – | – |
|
20
iTeos Therapeutics
ITOS
| $119M | 1.65% | 4,417,259 | – | – |
|
21
Day One Biopharmaceuticals
DAWN
$769M
| $118M | 1.63% | 4,965,588 | – | – |
|
|
IMGN
22
DELISTED
Immunogen Inc
IMGN
| $104M | 1.45% | 18,417,458 | – | – |
|
23
Phathom Pharmaceuticals
PHAT
$864M
| $100M | 1.39% | 3,115,008 | – | – |
|
24
Vaxcyte
PCVX
$4B
| $98.9M | 1.37% | 3,896,865 +31,057 | +0.8% | +$788K |
|
25
89bio
ETNB
$1.34B
| $97.3M | 1.35% | 4,965,769 | – | – |
|